Solid Tumor Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

CPMC offers the following clinical studies in solid tumors:

Molecular Analysis for Therapy Choice (MATCH)

Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 y/o and older, with a have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival

Status

Contact site for study status

Contacts

Peter Gasper, 415-600-3472

An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Description: This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, with histologically documented, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen and are not candidates for regimens known to provide clinical benefit

Status

Active and open to enrollment

Contacts

Leslie Corona, 415-600-5766

Title: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer  (NCT02240238)

Description: Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, who have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy; or who have histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC and have received 1 or 2 lines of prior chemotherapy or targeted therapy for Stage IIIB or IV NSCLC (second- or third-line)

Status

Active and open to enrollment
 

Contacts

Leslie Corona, 415-600-5766

 

Title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications  (NCT02517398)

Description: The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks.

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, with measurable disease with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Status

Active and open to enrollment

Contacts

Leslie Corona, 415-600-5766

 

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors (NCT01803282)

Description: This is an open-label, multicenter, sequential dose-escalation, and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5745 alone and in combination with chemotherapy.

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, with histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available

Status

Active and open to enrollment

Contacts

Leslie Corona, 415-600-5766